STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

KRYS KRYSTAL BIOTECH INCORPORATED StockScouter® Report

4

StockScouter® Score

KRYSTAL BIOTECH INCORPORATED, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • The ratio of KRYS’s forward price-to-earnings multiple to its estimated growth rate is below the average of comparably-sized companies in the StockScouter universe. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • One or more analysts has modestly decreased quarterly earnings estimates for KRYS. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 40% done.
Progress: 60% done.
Low
High

Core Model Grades

C
C
F
C

Previous Ratings

5
7
6